Individuals with a deleterious mutation in 1 of 2 breast cancer susceptibility genes, BRCA1 (OMIM 113705) or BRCA2 (OMIM 600185), face a high lifetime risk of developing ovarian cancer, estimated to be 49% for a BRCA1 mutation and 21% for a BRCA2 mutation.1 Risk-reducing or prophylactic bilateral salpingo-oophorectomy (ie, surgical removal of ovaries and fallopian tubes) is recommended given that effective screening or chemoprevention options are currently lacking for this high-risk population. The gene discussed is BRCA1; the disease is breast cancer.